<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051307</url>
  </required_header>
  <id_info>
    <org_study_id>MPN19H2</org_study_id>
    <nct_id>NCT04051307</nct_id>
  </id_info>
  <brief_title>Dual Vaccine Trial in Myeloproliferative Neoplasms</brief_title>
  <official_title>Dual Vaccine Trial in Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inge Marie Svane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1
      peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to
      vaccination and subsequently safety, toxicity and clinical effect.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">July 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>1 year</time_frame>
    <description>T-cell cytokine release towards target antigens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events evaluated by CTCAE v. 5.0</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events are graded 1-5 according to the criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>10 year</time_frame>
    <description>Vaccinations will induce clinical response in 2 patients, either partial response or better, according response criteria for PV and ET or clinical response as a reduction of mutated allelic burden - 10% from baseline at any time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with:
PD-L1 peptide:
PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.
Arginase1 peptide:
ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.
Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL</intervention_name>
    <description>Peptide vaccination</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>PD-L1Long</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL</intervention_name>
    <description>Peptide vaccination</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>ARGLong2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of essential thrombocythemia or Polycythemia Vera, according to the WHO
             criteria123,124 2. Age ≥18 years 3. Performance status ≤ 2 (ECOG-scale) 4. Expected
             survival &gt; 3 months 5. Sufficient bone marrow function 6. Creatinine &lt; 2.5 upper
             normal limit, i.e. &lt; 300 µmol/l 7. Sufficient liver function, i.e.

               1. ALAT &lt; 2.5 upper normal limit, i.e. ALAT &lt;112 U/l

               2. Bilirubin &lt; 30 U/l 8. For women: Agreement to use contraceptive methods with a
                  failure rate of &lt; 1% per year during the treatment period and for at least 120
                  days after the last treatment.

                  9. For men: Agreement to use contraceptive measures and agreement to refrain from
                  donating sperm.

                  Exclusion criteria

                    1. Other malignancies in the medical history excluding basal cell carcinoma.
                       Patients cured for another malignant disease with no sign of relapse five
                       years after ended treatment is allowed to enter the protocol.

                    2. Significant medical condition per investigators judgement e.g. severe
                       Asthma/COPD, poorly regulated heart condition, insulin dependent diabetes
                       mellitus.

                    3. Acute or chronic viral or bacterial infection e.g. HIV, hepatitis or
                       tuberculosis

                    4. Serious known allergies or earlier anaphylactic reactions.

                    5. Known sensibility to Montanide ISA-51

                    6. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia
                       or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia
                       gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency,
                       autoimmune thyroiditis etc.

                    7. Pregnant and breastfeeding women.

                    8. Fertile women not using secure contraception with a failure rate less than &lt;
                       1%

                    9. Patients taking immune suppressive medications incl. systemic
                       corticosteroids and methotrexate at the time of enrollment

                   10. Psychiatric disorders that per investigator judgment could influence
                       compliance.

                   11. Treatment with other experimental drugs

                   12. Treatment with other anti-cancer drugs - except IFN-a, hydroxyurea or
                       anagrelide.

                   13. Treatment with ruxolitinib.

                   14. Treatment with chemotherapy or immune therapy (excluding IFN-a, hydroxyurea
                       or anagrelide) within the last 28 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob H Grauslund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTER FOR CANCER IMMUNE THERAPY, CCIT-DK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob H Grauslund, MD</last_name>
    <phone>+4538688961</phone>
    <email>jgra0033@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Capital Region</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob H Grauslund, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Cancer Immune Therapy (CCIT-DK)</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob H Grauslund, MD</last_name>
      <phone>+4538688961</phone>
      <email>jgra0033@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inge Marie Svane</investigator_full_name>
    <investigator_title>Prof, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

